AKTX - Akari Therapeutics, Plc

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.2900
-0.0500 (-2.14%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous Close 2.3400
Open 2.4000
Bid 2.2000 x 800
Ask 2.6500 x 800
Day's Range 2.2600 - 2.4784
52 Week Range 1.5600 - 9.2000
Volume 72,853
Avg. Volume 2,426,993
Market Cap 36.312M
Beta (3Y Monthly) 1.17
PE Ratio (TTM) N/A
EPS (TTM) N/A
Earnings Date N/A
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est N/A
  • Benzinga last month

    The Daily Biotech Pulse: FDA Greenlights AbbVie's Psoriasis Drug, Novartis Earnings, Patent Notification For MediciNova

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on April 22) BIONDVAX PHARMA/S ADR (NASDAQ: BVXV ) Eidos Therapeutics ...

  • Benzinga last month

    Microcap Biotech Akari Rallies On Coversin Trial Results

    Akari Therapeutics PLC (NASDAQ: AKTX ) shares were surging Tuesday, breaking above the $4 barrier for the first time in about a month. What Happened The microcap biotech — which focuses on therapies for ...

  • What Kind Of Shareholders Own Akari Therapeutics, Plc (NASDAQ:AKTX)?
    Simply Wall St. 2 months ago

    What Kind Of Shareholders Own Akari Therapeutics, Plc (NASDAQ:AKTX)?

    Every investor in Akari Therapeutics, Plc (NASDAQ:AKTX) should be aware of the most powerful shareholder groups. Insiders often own a large chunk of younger, smaller, companies while huge companies tendRead More...

  • Benzinga 2 months ago

    The Daily Biotech Pulse: Arsanis Completes X4 Merger, EC Nod For Roche, Axovant Offering

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 13) Abbott Laboratories (NYSE: ABT ) Akari Therapeutics ...

  • MarketWatch 2 months ago

    Akari Therapeutics' stock rockets on massive volume after 'successful' pre-IND FDA meeting

    Shares of Akari Therapeutics PLC more than doubled--soaring 145%--toward a 15-month high in very active morning trade Wednesday, enough to pace all the gainers on the Nasdaq exchange, after the company said it plans to commence trials in European and U.S. pediatric patients this year for its treatment of pediatric thrombotic microangiopathy. Trading volume rocketed to 22.3 million shares, compared with the full-day average of about 20,000 shares. The company said it had a "successful," pre-investigational new drug (IND) meeting with the Food and Drug Administration regarding its pivotal clinical trial program for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA), which is an orphan condition with an estimated fatality rate of 80%. Chief Executive Clive Richardson said trials in HSCT-TMA patients are planned to begin in the fourth quarter. "We see HSCT-TMA as a gateway indication into a range of other poorly treated orphan TMAs, and are enthusiastic about the potential of Coversin to offer an improved standard of care for patients with these rare and usually fatal conditions," Richardson said. The stock has now run up 93% over the past 12 months, while the iShares Nasdaq Biotechnology ETF has slipped 1.1% and the S&P 500 gained 0.9%.

  • Alexion's (ALXN) Earnings Beat Estimates in Q4, Shares Up
    Zacks 4 months ago

    Alexion's (ALXN) Earnings Beat Estimates in Q4, Shares Up

    Alexion (ALXN) exceeds earnings and sales estimates in the fourth quarter of 2018 on strong performance by Soliris.

  • Alexion's Ultomiris Meets Primary Endpoint in aHUS Study
    Zacks 4 months ago

    Alexion's Ultomiris Meets Primary Endpoint in aHUS Study

    Alexion's (ALXN) Ultomiris meets primary endpoint in a phase III study conducted on complement inhibitor-naive patients with aHUS.

  • What You Must Know About Akari Therapeutics, Plc’s (NASDAQ:AKTX) Beta Value
    Simply Wall St. 5 months ago

    What You Must Know About Akari Therapeutics, Plc’s (NASDAQ:AKTX) Beta Value

    If you own shares in Akari Therapeutics, Plc (NASDAQ:AKTX) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...

  • How Do Analysts See Akari Therapeutics Plc (NASDAQ:AKTX) Performing In The Years Ahead?
    Simply Wall St. last year

    How Do Analysts See Akari Therapeutics Plc (NASDAQ:AKTX) Performing In The Years Ahead?

    Akari Therapeutics Plc’s (NASDAQ:AKTX) latest earnings announcement in December 2017 confirmed company earnings became less negative compared to the previous year’s level as a result of recent tailwinds Below, I’veRead More...